SUPPLEMENTAL TABLES AND FIGURES

Pembrolizumab Plus Axitinib versus Sunitinib in Metastatic Renal Cell Carcinoma: Outcomes of Japanese Patients Enrolled in the Randomized, Phase 3, Open-Label KEYNOTE 426 Study

Satoshi Tamada,1 Chihiro Kondoh,2 Nobuaki Matsubara,3 Ryuichi Mizuno,4 Go Kimura,5 Satoshi Anai,6 Yoshihiko Tomita,7 Masafumi Oyama,8 Naoya Masumori,9 Takahiro Kojima,10 Hiroaki Matsumoto,11 Mei Chen,12 Mengran Li,13* Kenji Matsuda,13 Yoshinobu Tanaka,13 Brian I. Rini,14 Hirotsugu Uemura15

1Bell Land General Hospital, Osaka, Japan; 2Toranomon Hospital, Tokyo, Japan; 3National Cancer Center Hospital East, Kashiwa, Japan; 4Keio University Hospital, Tokyo, Japan; 5Nippon Medical School Hospital, Tokyo, Japan; 6Nara Medical University Hospital, Kashiwara, Japan; 7Niigata University Medical & Dental Hospital, Niigata, Japan; 8Saitama Medical University International Medical Center, Saitama, Japan; 9Sapporo Medical University, Sapporo, Japan; 10University of Tsukuba, Tsukuba, Japan; 11Yamaguchi University, Yamaguchi, Japan; 12Merck & Co., Inc., Kenilworth, NJ, USA; 13MSD K.K., Tokyo, Japan; 14Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA; currently at Vanderbilt-Ingram Cancer Center, Nashville, TN, USA; 15Kindai University, Osaka, Japan

*At the time the study was conducted

Corresponding author
Satoshi Tamada
Higashiyama 500-3, Naka-ku, Sakai City, Osaka, 599-8247, Japan
satoshitamada@osaka.med.or.jp
|                              | Japanese Population | Global Population |
|------------------------------|---------------------|------------------|
|                              | Pembrolizumab + Axitinib (n = 44) | Sunitinib (n = 50) | Pembrolizumab + Axitinib (n = 432) | Sunitinib (n = 429) |
| Male, n (%)                  | 36 (82)             | 39 (78)          | 308 (71)                      | 320 (75)            |
| Age, years, median (range/IQR) | 66 (43–84)         | 65 (39–90)       | 62 (55–68)                    | 61 (53–68)          |
| Age, n (%)                   |                     |                  |                               |                    |
| <65                          | 20 (45)             | 25 (50)          | 260 (60)                      | 278 (65)            |
| ≥65                          | 24 (55)             | 25 (50)          | 172 (40)                      | 151 (35)            |
| Karnofsky Performance Status Scale score, n (%) |                   |                  |                               |                    |
| 90/100                       | 39 (89)             | 48 (96)          | 346 (80)                      | 341 (79)            |
| 70/80                        | 5 (11)              | 2 (4)            | 85 (20)                       | 88 (21)             |
| IMDC risk category, n (%)    |                     |                  |                               |                    |
| Favorable                    | 19 (43)             | 16 (32)          | 138 (32)                      | 131 (31)            |
| Intermediate/poor            | 25 (57)             | 34 (68)          | 294 (68)                      | 298 (69)            |
| PD-L1 status, n (%)          |                     |                  |                               |                    |
| CPS ≥1                       | 25 (57)             | 31 (62)          | 242 (56)                      | 253 (59)            |
| CPS <1                       | 19 (43)             | 18 (36)          | 165 (38)                      | 156 (36)            |
| Missing                      | 0                   | 1 (2)            | 25 (6)                        | 20 (5)              |
| Sarcomatoid feature, n (%)   | 7 (16)              | 5 (10)           | 51 (12)                       | 54 (13)             |

CPS combined positive score; IMDC International Metastatic Renal Cell Carcinoma Database Consortium; IQR interquartile range; PD-L1 programmed death-ligand 1

*Range in the Japanese population; IQR in the global population

*One patient had missing information in the global population (pembrolizumab-axitinib group)
**Supplementary Table 2** Subsequent therapy after study drug discontinuation in the Japanese population

|                          | Pembrolizumab + Axitinib ($n = 44$) | Sunitinib ($n = 50$) |
|--------------------------|-------------------------------------|----------------------|
| Discontinued study treatment | 33 (75)                            | 42 (84)              |
| Received any subsequent systemic anticancer therapy after discontinuation$^a$ | 24 (73)                            | 39 (93)              |
| Any VEGF/VEGFR inhibitor$^b$ | 18 (55)                            | 26 (62)              |
| Nivolumab$^c$             | 4 (12)                              | 28 (67)              |
| Other type$^d$            | 6 (18)                              | 4 (10)               |
| 1 subsequent line         | 24 (73)                             | 39 (93)              |
| 2 subsequent lines        | 6 (18)                              | 19 (45)              |
| $\geq$3 subsequent lines  | 1 (3)                               | 6 (14)               |

*PD-L1* programmed death ligand 1; *VEGF* vascular endothelial growth factor; *VEGFR* vascular endothelial growth factor receptor

$^a$Percentages are calculated with 33 discontinuations as the denominator

$^b$Axitinib, cabozantinib, pazopanib, sorafenib, or sunitinib

$^c$Only PD-L1 inhibitor used as subsequent therapy

$^d$Everolimus, interferon (unspecified), investigational drug (unspecified), ipilimumab, temsirolimus.
| AEs of interest                  | Pembrolizumab-axitinib (n = 44) |               |               | Sunitinib (n = 49) |               |               |
|---------------------------------|---------------------------------|---------------|---------------|-------------------|---------------|---------------|
|                                 | Any grade                       | Grade 1/2     | Grade 3/4     | Any grade         | Grade 1/2     | Grade 3/4     |
| Any                             | 28 (63.6)                        | 20 (45.5)     | 8 (18.2)      | 26 (53.1)         | 26 (53.1)     | 0             |
| Hypothyroidism                  | 15 (34.1)                        | 15 (34.1)     | 0             | 21 (42.9)         | 21 (42.9)     | 0             |
| Hyperthyroidism                 | 7 (15.9)                         | 7 (15.9)      | 0             | 2 (4.1)           | 2 (4.1)       | 0             |
| Adrenal insufficiency           | 5 (11.4)                         | 5 (11.4)      | 0             | 0                 | 0             | 0             |
| Colitis                         | 5 (11.4)                         | 2 (4.5)       | 3 (6.8)       | 0                 | 0             | 0             |
| Pneumonitis                     | 3 (6.8)                          | 2 (4.5)       | 1 (2.3)       | 1 (2.0)           | 1 (2.0)       | 0             |
| Thyroiditis                     | 3 (6.8)                          | 3 (6.8)       | 0             | 2 (4.1)           | 2 (4.1)       | 0             |
| Myasthenic syndrome             | 2 (4.5)                          | 2 (4.5)       | 0             | 0                 | 0             | 0             |
| Myositis                        | 2 (4.5)                          | 2 (4.5)       | 0             | 0                 | 0             | 0             |
| Hepatitis                       | 1 (2.3)                          | 0             | 1 (2.3)       | 0                 | 0             | 0             |
| Hypophysitis                    | 1 (2.3)                          | 0             | 1 (2.3)       | 0                 | 0             | 0             |
| Infusion reactions              | 1 (2.3)                          | 1 (2.3)       | 0             | 1 (2.0)           | 1 (2.0)       | 0             |
| Myocarditis                     | 1 (2.3)                          | 0             | 1 (2.3)       | 0                 | 0             | 0             |
| Nephritis                       | 1 (2.3)                          | 1 (2.3)       | 0             | 1 (2.0)           | 1 (2.0)       | 0             |
| Severe skin reactions           | 1 (2.3)                          | 0             | 1 (2.3)       | 1 (2.0)           | 1 (2.0)       | 0             |
| Uveitis                         | 1 (2.3)                          | 1 (2.3)       | 0             | 0                 | 0             | 0             |

Data are n (%) and are from the as-treated population.
Supplementary Figure 1. Patient disposition of the Japanese population. AE adverse event; CR complete response; PD progressive disease

94 Patients in Japan Randomized

Pembrolizumab + Axitinib
44 allocated
44 treated

7 (16%) ongoing
33 (75%) discontinued
11 (25%) AEs
17 (39%) PD
4 (9%) patient decision
1 (2%) CR

Sunitinib
50 allocated
49 treated

7 (14%) ongoing
42 (86%) discontinued
13 (27%) AEs
24 (49%) PD
3 (6%) patient decision
2 (4%) physician decision

*Afour patients completed 2 full years of pembrolizumab.*